drugset / Trial / NCT02318095
Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research protocol will evaluate the feasibility of administering neoadjuvant gemcitabine and nab-paclitaxel with hypofractionated, image guided, intensity modulated radiotherapy (HIGRT) in resectable and borderline resectable pancreatic cancer
Timeline
- Start
- 2015-02-17
- Primary completion
- 2018-11-07
- Completion
- 2022-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | — |